Lilly Continues Alzheimer's Efforts

Posted: Updated:
SAN DIEGO -

Eli Lilly and Co. (NYSE: LLY) is today releasing detailed results of a once-promising Alzheimer's disease treatment and announcing a partnership on another potential treatment of the disease. As a result of shelving solanezumab, Lilly said last week it plans to cut some of its work force. The codevelopment agreement with AstraZeneca PLC (NYSE: AZN) involves an antibody currently in Phase 1 trials.

The pharmaceutical makers say the collaboration builds on an existing relationship related to another drug currently in two late-stage trials.

Lilly says the hope is that MEDI1814 could slow the progression of Alzheimer's Disease when it binds with a peptide in the brain linked to the disease. Lilly Research Laboratories President Jan Lundberg says "we are pleased to be expanding our alliance with AstraZeneca to further build our pipeline of potential medicines and diagnostic agents. AstraZeneca brings capabilities and expertise and most importantly shares our passion to bring new medicines to patients suffering from this debilitating illness."

Lilly will pay AstraZeneca $30 million upfront under the arrangement.

At the global Clinical Trials on Alzheimer's Disease meeting Thursday in San Diego, Lilly presented results of its late-stage trial of solanezumab. The company will no longer pursue regulatory approval for the drug that had shown potential in previous development stages to treat mild dementia caused by Alzheimer's Disease. Distinguished Medical Fellow Eric Siemers said "the results of EXPEDTION3 are without question disappointing. However, Lilly remains committed to finding solutions for this devastating disease. We will continue to analyze study results and work with the external scientific community in the hopes of uncovering findings that will help shape and advance future Alzheimer's disease research."

You can connect to more about the AstraZeneca partnership by clicking here and the solanezumab details by clicking here.

  • Perspectives

    • School District Raises Questions About ILEARN

      Like all schools in Indiana, we were disheartened at the ILEARN results for school year 2018. We would like to raise several questions concerning this test as it relates to college and career readiness for our students. The annual Indiana Statewide Assessment (this year’s ILEARN) has been developed to evaluate college and career readiness at all levels tested. We are very troubled by our lack of understanding of what indicators in the test evaluate...

    More

Events



  • Most Popular Stories

    • Purdue University ranks #7 for Best Value in a college education in the U.S., according to the Wall Street Journal

      Two Indiana Schools Break Top 50 List of Best Colleges

      The Wall Street Journal and the Times Higher Education magazine have released their annual list of the top 801 colleges and universities in the country. Two Hoosier universities are included in the top 50.

    • Purdue to Open Chick-Fil-A Amid Protests

      Citing overwhelming demand for Chick-fil-A’s food and services, Purdue University has announced it will allow the restaurant to open on campus. The university has been at the center of a debate over the Georgia-based food chain. 

    • Buttigieg to Lead Task Force on Automation

      South Bend Mayor Pete Buttigieg will Friday launch a task force aimed at preparing for the effects of automation at the U.S. Conference of Mayors Winter Meeting. The mayor's office says “Automation and the Impacts on America’s Cities” will include mayors from throughout the country.

    • Sports betting is now legal in Indiana

      Protecting Data Integrity as Sports Betting Grows in Indiana

      Casinos across the state are opening sports betting parlors this week, legally allowing gamblers in Indiana to place bets on professional and some collegiate sports. Some opponents of the law are concerned the integrity of sports is at risk. Others are worried about the integrity of the data used by odds makers in the now-legal betting houses. “There's a mechanism in place that can stop that from happening, or curtail it from happening in the future,” explains...

    • (photo courtesy Cummins)

      Cummins Completes Deal for Fuel Cells Producer

      Columbus-based Cummins Inc. (NYSE: CMI) has closed on its acquisition of Hydrogenics Corp., a fuel cell systems provider in Canada. Cummins says the $290 million deal helps push the company towards a wider range of power technologies, including fuel cells and hydrogen-fueled sectors.